Will New Ratings Coverage by Wells Fargo Help Kezar Life Sciences (KZR) Stock This Week?

July 16, 2018 - By Jason Dias

Why Has Wells Fargo Given Kezar Life Sciences (KZR) a $30.0 Price Target

The broker Wells Fargo has today initiated coverage on Kezar Life Sciences (KZR) shares, with a Outperform rating, while giving it the target at $30.0.

The stock increased 2.09% or $0.33 during the last trading session, reaching $16.13. About 59,995 shares traded. Kezar Life Sciences, Inc. (KZR) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company has market cap of $307.62 million.

More notable recent Kezar Life Sciences, Inc. (NASDAQ:KZR) news were published by: Prnewswire.com which released: “Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to …” on June 25, 2018, also Prnewswire.com with their article: “Kezar Life Sciences Announces Pricing of Initial Public Offering” published on June 21, 2018, Investorplace.com published: “8 Biotech Stocks With IPOs This Week” on June 20, 2018. More interesting news about Kezar Life Sciences, Inc. (NASDAQ:KZR) were released by: Nasdaq.com and their article: “Nasdaq’s Hot First Day of Summer – Six IPOs Join our Market” published on June 22, 2018 as well as Bizjournals.com‘s news article titled: “Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M” with publication date: June 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.